US 12,331,326 B2
Genetically engineered Vibrio sp. and uses thereof
Matthew T Weinstock, San Diego, CA (US); Christopher M. Wilson, San Diego, CA (US); and Eric D. Hesek, Carlsbad, CA (US)
Assigned to Telesis Bio Inc, San Diego, CA (US)
Filed by Codex DNA, Inc., San Diego, CA (US)
Filed on Sep. 9, 2022, as Appl. No. 17/941,373.
Application 17/941,373 is a division of application No. 16/525,349, filed on Jul. 29, 2019, granted, now 11,447,755.
Application 16/525,349 is a division of application No. 15/367,106, filed on Dec. 1, 2016, granted, now 10,377,997, issued on Aug. 13, 2019.
Claims priority of provisional application 62/261,758, filed on Dec. 1, 2015.
Prior Publication US 2023/0027483 A1, Jan. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12P 21/00 (2006.01); C12N 1/21 (2006.01); C12N 9/12 (2006.01); C12N 15/74 (2006.01); C12P 19/34 (2006.01)
CPC C12N 9/1247 (2013.01) [C12P 19/34 (2013.01); C12P 21/00 (2013.01); C12Y 207/07006 (2013.01)] 15 Claims
 
1. A method of producing a biomolecule comprising:
a) contacting a Vibrio natriegens organism with a vector and introducing the vector into the Vibrio natriegens organism, wherein the vector comprises a heterologous nucleic acid encoding the biomolecule, wherein the Vibrio natriegens organism comprises a recombinant nucleic acid comprising a nucleotide sequence encoding a T7 RNA polymerase and a recombinant regulatory element 5′ to the nucleotide sequence encoding the T7 RNA polymerase that regulates expression of the T7 RNA polymerase, and wherein the recombinant regulatory element comprises a ribosome binding site having at least 95% sequence identity to SEQ ID NO: 8;
b) expressing the heterologous nucleic acid in a cell-free extract of the Vibrio natriegens organism, thereby producing the biomolecule; and
c) isolating the biomolecule.